期刊
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
卷 198, 期 4, 页码 424-439出版社
AMER THORACIC SOC
DOI: 10.1164/rccm.201806-1160ST
关键词
right ventricle; pulmonary hypertension; pulmonary embolism; acute respiratory distress syndrome; pulmonary circulation
资金
- Eli Lilly
- Gilead
- Pfizer
- United Therapeutics
- Ikaria
- Janssen
- Eiger
- GlaxoSmithKline
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL122417] Funding Source: NIH RePORTER
- Veterans Affairs [I01BX002042] Funding Source: NIH RePORTER
Background: Right ventricular (RV) adaptation to acute and chronic pulmonary hypertensive syndromes is a significant determinant of short- and long-term outcomes. Although remarkable progress has been made in the understanding of RV function and failure since the meeting of the NIH Working Group on Cellular and Molecular Mechanisms of Right Heart Failure in 2005, significant gaps remain at many levels in the understanding of cellular and molecular mechanisms of RV responses to pressure and volume overload, in the validation of diagnostic modalities, and in the development of evidence-based therapies. Methods: A multidisciplinary working group of 20 international experts from the American Thoracic Society Assemblies on Pulmonary Circulation and Critical Care, as well as external content experts, reviewed the literature, identified important knowledge gaps, and provided recommendations. Results: This Executive Summary includes key recommendations and provides a prioritized pathway for addressing pertinent preclinical and clinical research gaps. The group identified knowledge gaps and research opportunities in three major topic areas: 1) optimizing the methodology to assess RV function in acute and chronic conditions in preclinical models, human studies, and clinical trials; 2) analyzing advanced RV hemodynamic parameters at rest and in response to exercise; and 3) deciphering the underlying molecular and pathogenic mechanisms of RV function and failure in diverse PH syndromes. Conclusions: This statement provides a roadmap to further advance the state of knowledge, with the ultimate goal of developing RV-targeted therapies for patients with RV failure of any etiology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据